CMPX logo

CMPX
Compass Therapeutics Inc

650
Mkt Cap
$871.52M
Volume
620,206.00
52W High
$5.11
52W Low
$1.33
PE Ratio
-10.71
CMPX Fundamentals
Price
$4.85
Prev Close
$4.90
Open
$4.92
50D MA
$3.99
Beta
1.53
Avg. Volume
1.8M
EPS (Annual)
-$0.3594
P/B
4.15
Rev/Employee
$24,285.71
Loading...
Loading...
News
all
press releases
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month High - Here's Why
Compass Therapeutics (NASDAQ:CMPX) Hits New 1-Year High - Here's Why...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
FY2029 EPS Estimates for Compass Therapeutics Cut by Wedbush
Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Analysts at Wedbush reduced their FY2029 earnings estimates for shares of Compass Therapeutics in a research note issued to investors on...
MarketBeat·12d ago
News Placeholder
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Beats Estimates By $0.06 EPS
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share for the quarter, topping the consensus...
MarketBeat·14d ago
News Placeholder
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from D. Boral Capital
D. Boral Capital reissued a "buy" rating and issued a $30.00 target price on shares of Compass Therapeutics in a report on Wednesday...
MarketBeat·14d ago
News Placeholder
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Compass Therapeutics (CMPX Research Report) today and set a price target of $10...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating Affirmed: Compass Therapeutics' Promising Pipeline and Prudent Financial Outlook
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics (CMPX Research Report) and keeping the price target...
TipRanks Financial Blog·1y ago
News Placeholder
CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·2y ago
News Placeholder
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line...
Globe Newswire·2y ago
News Placeholder
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Globe Newswire·2y ago
News Placeholder
Compass Therapeutics announces publication of CTX-8371 preclinical data
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest CMPX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.